Top 5 High Tech Stocks To Own Right Now

MicroVision, Inc. (NASDAQ:MVIS) has been quietly churning out high tech imaging and laser scanning technology for years. But MVIS stock began to soar last fall on news it was developing a lidar system for the automotive sector.

Source: temp-64GTX/

Between the start of December 2020 and Feb. 16 of this year, MVIS stock rocketed up by more than 920%. After a quick correction, it’s surged several times since, hitting a decade-long high close of $26.44 on April 26.

Top 5 High Tech Stocks To Own Right Now: Atlantic American Corporation(AAME)

Atlantic American Corporation, through its subsidiaries, provides life and health, and property and casualty insurance products in the United States. Its property and casualty insurance products include business automobile insurance coverage for state governments, local municipalities, and other motor pools and fleets; and business personal property, inland marine, and general liability products. The company also offers surety bond coverage for school bus transportation and subdivision construction, as well as performance and payment bonds. In addition, it provides life and supplemental health products, including ordinary and term life insurance, Medicare supplement, and other accident and health insurance products. The company markets its products through independent agents. Atlantic American Corporation was founded in 1968 and is headquartered in Atlanta, Georgia.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Bovie Medical Corp  (NYSEMKT:BVX)Q4 2018 Earnings Conference CallMarch 13, 2019, 4:30 p.m. ET

    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:


  • [By Ethan Ryder]

    TheStreet upgraded shares of Bovie Medical (NYSEAMERICAN:BVX) from a d rating to a c- rating in a research report report published on Monday morning.

  • [By Lisa Levin] Gainers
    Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results.
    MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40.
    MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia.
    Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors.
    Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58.
    Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82.
    Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82.
    Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings.
    Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69.
    PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results.
    Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42.
    LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results.
    Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results.
    Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37.
    Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close

Top 5 High Tech Stocks To Own Right Now: Dupont Fabros Technology, Inc.(DFT)

DuPont Fabros Technology, Inc. (“DFT”) was formed on March 2, 2007, is a real estate investment trust, or REIT, and is headquartered in Washington, D.C. DFT is the sole general partner of, and, as of December 31, 2015, owned 81.4% of the common economic interest in DuPont Fabros Technology, L.P. (the “Operating Partnership” or “OP”). Unless otherwise indicated or unless the context requires otherwise, all references to “we,” “us,” “our,” “our company” or “the company” refer to DFT and the Operating Partnership, collectively. We design and operate innovative, multi-tenant, wholesale data centers, and create solutions with our customers that free them to focus on their core businesses. Our facilities are designed to offer highly specialized, efficient and safe computing environments in a low-cost operating model.   Advisors’ Opinion:

  • [By Shane Hupp]

    DigiFinexToken (CURRENCY:DFT) traded 0.6% lower against the U.S. dollar during the twenty-four hour period ending at 19:00 PM Eastern on March 8th. One DigiFinexToken token can currently be purchased for about $0.17 or 0.00004327 BTC on exchanges. During the last week, DigiFinexToken has traded 12.7% higher against the U.S. dollar. DigiFinexToken has a total market capitalization of $0.00 and $984,872.00 worth of DigiFinexToken was traded on exchanges in the last 24 hours.

  • [By Shane Hupp]

    DraftCoin (CURRENCY:DFT) traded 1.5% lower against the U.S. dollar during the 1 day period ending at 9:00 AM Eastern on October 9th. During the last seven days, DraftCoin has traded 0.7% lower against the U.S. dollar. DraftCoin has a total market cap of $185,310.00 and approximately $3,088.00 worth of DraftCoin was traded on exchanges in the last 24 hours. One DraftCoin coin can now be bought for about $0.0231 or 0.00000351 BTC on exchanges including CoinExchange, YoBit and Coindeal.

Top 5 High Tech Stocks To Own Right Now: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Its lead product candidate, Resunab, is a novel oral anti-inflammatory drug that is expected to commence Phase IIa clinical trials for the treatment of cystic fibrosis and diffuse systemic sclerosis diseases. The company is based in Norwood, Massachusetts.

Leave a Reply

Your email address will not be published.